<DOC>
	<DOC>NCT02924155</DOC>
	<brief_summary>This study is a randomized, double-blind, placebo-controlled, single day/multiple day dosing, Phase I clinical trial to investigate the systemic exposure, safety and local tolerability of SJP002 ophthalmic solution in healthy Korean male volunteers.</brief_summary>
	<brief_title>Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Healthy Korean male 2050 years old Present condition or history of any clinically significant disease History of hypersensitivities, including drug allergies Present condition or history of following diseases; History of Keratitis, Uveitis, Retinitis, or Dry eye syndrome, Corrective sight scale below 20/40(0.5), Present of adverse reaction after wearing contact lens or plan to wear contact lens, History of ophthalmic surgery. Drug abuse within 60 days, or a positive reaction to Drug testing in Urine Taken any ETC of herbal supplement within 14 days or any OTC or vitamin supplement within 7 days Participation in and administration of IP of another clinical trial within 90 days Donation of whole blood within 60 days or blood components within 30 days, or receipt of blood transfusion within 30 days Consumption of more than 21 units of alcohol/week or inability to abstain from drinking during the study period Smoking within 90 days Plan to be pregnant, or not to use an appropriate method of contraception</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>